



Fifth EDCTP forum – Tanzania 2009

# The ADRB assay: a new tool, correlated with clinical protection from *Plasmodium falciparum* malaria, to test malaria vaccine.

Charlotte Joos <sup>(1,2)</sup> , Laurence Marrama <sup>(3)</sup> , Hannah E.J. Polson <sup>(2)</sup> ,  
Aïssatou Touré <sup>(1)</sup> , Ronald Perraut <sup>(1)</sup> & Shirley Longacre <sup>(2)</sup> .



INSTITUT PASTEUR  
DE DAKAR

(1) Unité d'Immunologie, Institut Pasteur de Dakar,  
Sénégal


(2) Laboratoire de Vaccinologie Parasitaire, Institut  
Pasteur, Paris, France

(3) Unité d'Epidémiologie, Institut Pasteur de Dakar,  
Sénégal




INSTITUT PASTEUR

# The Antibody Dependant Respiratory Burst (ADRB)



Polymorphonuclear  
neutrophil

# The ADRB detected by chemiluminescence (CL) - Methodology



# Standardization of results for reproducibility

- Positive standard (HIS) in the first and last wells
- ADRB index determination:


$$1000 * (\text{Max rlu tested sera}) / (\text{Max rlu (average) HIS})$$

- Induce good inter-trials reproducibility:  $\approx 80\%$
- No responder in ADRB assay :  $\text{ADRB} < 250$  units

# IgG opsonized on merozoite induce the ADRB response


- Merozoite or sera alone : no signal
- No effect of Complement
- Total IgG depleted sera: lost of signal

# Two study sites with two endemic profiles





	NDIOP	DIELMO
<b>ENDEMICITY</b>	Mesoendemic	Holoendemic
<b>TRANSMISSION</b>	Seasonal	Perennial
<b>INFECTIVE BITES</b>	≈ 20 / inhabitant / year	≈ 1 / inhabitant / DAY
<b>MORE SENSIBLE AGE GROUP</b>	< 15 years RR = 13.1	< 6 years RR = 87.5
<b>IMMUNE AGE GROUP</b>	≥ 30 years RR = 1	≥ 15 years RR = 1

# IgG1 and IgG3 opsonized on merozoite induce the ADRB response



88 aparasitemic Ndiop residents tested

# Significant correlations between ADRB and clinical protection



**RR=1.8 if ADRB<250 (5.5months)  $P = 0.036$**

(in multivariate model: ADRB + age)

114 inhabitants of each village tested

**RR=17.5 if ADRB<250 (5.5months)  $P = 0.006$**

(in multivariate model: ADRB + age + Hb<sup>8</sup>)

# 2 ways to study effect of Ab anti-MSP1p19 in the ADRB assay

## ➤ USED OF ANTI-MSP1p19 DEPLETED SERA

1. Antigenic (Bv) catching of specific Ab
2. His-tag catching of complex Ag-Ab

Efficacy : 99%

**Lack of Ab  
anti-BvMSP1p19**

## ➤ USED OF ISOGENIC MEROZOITE CLONES


- D10-PcMEGF :  
*P. falciparum* genetically modified  
*P. chabaudi* MSP1p19 EGF domains  
No cross react

**Mz no recognized by  
Ab anti-Pf MSP1p19**

O'Donnell et al., J. Exp. Med. 2001, 193


# Ab anti-MSP1p19 induce 1/3 of the ADRB response

## Sera vs depleted sera



A  
D  
R  
B

## Normal vs transgenic mz



Lack of 32% of ADRB signal

Lack of 29% of ADRB signal

# CONCLUSION

- **An antibody functional assay statistically correlated with clinical protection in meso and holoendemic area.**
- **Importance of MSP1p19 vaccine (Bv)**
- **An assay to introduce in preclinical and clinical trials ?**



INSTITUT PASTEUR  
DE DAKAR

Comité International

Thank you



INSTITUT PASTEUR



UNIVERSITE  
PIERRE & MARIE CURIE  
LA SCIENCE A PARIS



cjoos@pasteur.sn